Document Detail


Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature.
MedLine Citation:
PMID:  19663116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Thalidomide is increasingly being used due to its effectiveness in the treatment of a variety of dermatologic conditions refractory to other treatments. Although thalidomide's side effects have been well-documented in the literature since its entry in the 1950s, some of the risks associated with its use are still being discovered. Recently, increased incidence of venous thrombosis following thalidomide use has been reported in the treatment of diseases with disease-related thrombotic risks, such as malignancy and lupus with antiphospholipid antibody syndrome, as well as concomitant therapy with chemotherapy and/or systemic corticosteroids. We report a case of deep venous thrombosis (DVT) and pulmonary embolus (PE) following thalidomide use in a patient with leprosy (erythema nodosum leprosum, ENL) who was concurrently treated with prednisone, as well as a review of relevant literature. Our findings substantiate an increase in risk for thrombosis following thalidomide use in the dermatology and non-cancer clinical setting.
Authors:
Sabrina Guillen Fabi; Carlotta Hill; Joslyn N Witherspoon; Susan L Boone; Dennis P West
Related Documents :
23953086 - Systematic reviews of complex interventions: framing the review question.
7479196 - Thrombolytic-associated cholesterol emboli syndrome: case report and literature review.
16167426 - Reticulate hyperpigmentation secondary to 5-fluorouracil and idarubicin.
16150036 - Inducing expertise effects in clinical case recall.
3967906 - Closed abdominal trauma in a child causing avulsion of the common bile duct and gastric...
2608096 - Tinea capitis in adults.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Journal of drugs in dermatology : JDD     Volume:  8     ISSN:  1545-9616     ISO Abbreviation:  J Drugs Dermatol     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-11     Completed Date:  2009-09-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160020     Medline TA:  J Drugs Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  765-9     Citation Subset:  IM    
Affiliation:
Department of Dermatology, University of Illinois at Chicago, College of Medicine, Chicago, IL, USA. sguillen@uic.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Drug Therapy, Combination
Erythema Nodosum / drug therapy
Humans
Leprostatic Agents / adverse effects*,  therapeutic use
Leprosy, Lepromatous / drug therapy
Male
Prednisone / therapeutic use
Pulmonary Embolism / chemically induced*
Thalidomide / adverse effects*,  therapeutic use
Venous Thrombosis / chemically induced*
Chemical
Reg. No./Substance:
0/Leprostatic Agents; 50-35-1/Thalidomide; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Alopecia areata treated with efalizumab: a case with significant hair re-growth after long-term ther...
Next Document:  The effects of corticosteroids on bone growth and bone density.